Jeffrey K. Francer Joins GPhA as Senior Vice President and General Counsel

PRESS RELEASE

WASHINGTON (October 24, 2016) Today the Generic Pharmaceutical Association (GPhA) announced that Jeffrey K. Francer will join the association as Senior Vice President and General Counsel beginning November 14, 2016. He will report to Chester “Chip” Davis, Jr., President and CEO, GPhA.

"I am thrilled to have Jeff join the GPhA leadership team to serve as our General Counsel," said Chip Davis, President and CEO of GPhA. "With his valuable experience working with the FDA, Congress, and biopharmaceutical companies, Jeff will be a strong advocate for our industry as we tackle complex issues including drug affordability during the next presidential administration and beyond.”

Francer previously served as Associate Chief Counsel of the FDA, where he counseled senior agency leaders on drug and biologics regulation, including manufacturing, clinical trials, and drug safety issues. Following his role at the FDA, Francer served as Associate General Counsel and U.S. Compliance Officer for Biogen, where he was the principal in-house counsel on regulatory issues and established the company's corporate compliance program. Francer joins GPhA from the Pharmaceutical Research and Manufacturers of America (PhRMA), where he serves as Vice President and Senior Counsel overseeing the association's regulatory law advocacy.

"The challenges facing our nation to provide safe, effective, and affordable health care to patients have never been greater," Francer said. "Enhancing generic and biosimilar competition, as well as ensuring the FDA's timely review of generic drugs, will be critical to addressing the needs of patients, and I'm excited to devote my energy to this mission."